Alipay+ Expands Payments and Digital Ecosystem as Mobile Wallets Become a Catalyst for New Travel Habits and Inclusive Growth
8.10.2025 06:16:00 CEST | Business Wire | Press Release
Alipay+ is Ant International’s global wallet gateway, enabling global merchants to accept payments from users of mobile wallets and digital banking apps around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251007877113/en/
Alipay+ empowers travellers to make cross-border payments and access travel services directly with their home e-wallets
To empower global tourism, Alipay+ has significantly expanded its payments and digital services ecosystem, in three ways:
- Payments: Growing cross-border payment acceptance for Alipay+ to more than 100 markets, and expanding its partner ecosystem to 40, representing 1.8 billion users
- Partners: Supporting [new] Bluecode (Europe), PayPay (Japan) and KBank (Thailand) users to pay with their banking and wallet apps when traveling abroad
- Services: New services include (i) Alipay+ Voyager, a built-in AI travel agent, integrating partners like Trip.com, Agoda and Grab, (ii) Alipay+ GenAI Cockpit, an AI-as-a-Service solution for digital wallets to build AI-native solutions, and (iii) Expanded Global Blue in-app tax refunds for more partners, creating an end-to-end digital experience
“Travel has a significant impact to local economies, and we believe that mobile wallets can be a catalyst for growth, connecting travellers and businesses in more ways than ever,” said Douglas Feagin, President of Ant International. “Alipay+ aims to support the travel ecosystem with AI-powered payments and digital services to enable online and offline merchants, tourism partners, and other fintechs to create customer-centric engagements for mobile-savvy consumers. Through greater collaboration, we can create a new future of travel, one that enhances the experience for consumers, and promotes growth and connectivity.
Mobile payments become the norm, driving inclusive growth for global merchants
Travellers are embracing the use of their trusted home payment app, with more than 6.5 million digital wallet users using Alipay+ cross-border payments for the first time in the first half of 2025. Transactions across online travel agents and in-store merchants increased by more than 30%1. Not only can travellers travel and pay “like a local” more conveniently, but now businesses can reach more customers easily.
To ensure inclusive growth at scale, Alipay+ is deepening its collaborations with national payment networks. Alipay+ transactions via national standardised QRs have almost doubled, as travellers can easily make payments at SMEs and merchants in smaller cities, including in destinations like South Korea, Malaysia, Singapore, Cambodia, Sri Lanka and more.
Short-haul, value-conscious travel on the rise, opening up more opportunities for local businesses
Travellers are seeking greater value when they travel by going to places closer to home, looking for deals, and spending at local merchants.
Asia is leading global travel growth in 2025, with intra-Asia travel a big contributor. China, Japan, South Korea, and particularly Southeast Asia are amongst the most popular travel destinations globally, with intra-Asia transactions by Alipay+ partners increasing 32 percent year-on-year.
Travellers want to save when they can, without compromising on experiencing local destinations. Redemptions via A+ Rewards, an in-app marketing platform where travellers can browse local promotions and coupons, increased 57 percent. Travellers are also spending more at local businesses, with transactions under USD10 increasing 37 percent.
While hotspots within Europe like France, Italy, Germany and the United Kingdom remain popular, destinations like Hungary, Greece and Norway saw the biggest growth in transactions, as travellers aim to explore new places while maximising their budgets.
Experiences and niche services in higher demand as travellers seek more conscious travel
Travellers are spending across more diverse travel scenarios beyond retail. While transactions for attractions and F&B continue to see significant growth, spending on local services including beauty, medical and education have become one of the key aspects of travel. For example, K-beauty transactions in South Korea increased 115 percent year-on-year.
Travellers are also going around more independently, with transactions on ride-hailing platforms doubling, and those on public transport increasing close to 50 percent. The expansion of Alipay+ acceptance across merchants and different modes of transportation has made it easier for travellers to visit smaller towns including Shikokuchūō in Japan, Jeollabuk-do in South Korea, Semporna in Malaysia and Phra Nakhon Si Ayutthaya Province in Thailand.
About Alipay+
Ant International's Alipay+ is a global wallet gateway with cross-border payment and digitisation services that help connect global merchants to consumers. Consumers enjoy seamless payments a broad choice of deals and the convenience of digital services using their preferred payment app/e-wallet while travelling abroad. Many small and medium-sized businesses already use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
1All Alipay+ data included are year-to-year comparison between H1 2025 and H1 2024
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007877113/en/
Contacts
Scott Lai, scott.lai@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom